Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Aligos Therapeutics (ALGS) EBIAT (2021 - 2025)

Aligos Therapeutics filings provide 5 years of EBIAT readings, the most recent being -$19.9 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 75.8% to -$19.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.2 million, a 81.56% increase, with the full-year FY2025 number at -$24.2 million, up 81.56% from a year prior.
  • EBIAT hit -$19.9 million in Q4 2025 for Aligos Therapeutics, up from -$31.5 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $43.1 million in Q1 2025 to a low of -$82.1 million in Q4 2024.
  • Median EBIAT over the past 5 years was -$22.4 million (2022), compared with a mean of -$23.4 million.
  • The widest YoY moves for EBIAT: up 223.59% in 2025, down 413.44% in 2025.
  • Aligos Therapeutics' EBIAT stood at -$37.7 million in 2021, then soared by 41.97% to -$21.9 million in 2022, then fell by 27.44% to -$27.9 million in 2023, then plummeted by 194.53% to -$82.1 million in 2024, then skyrocketed by 75.8% to -$19.9 million in 2025.
  • The last three reported values for EBIAT were -$19.9 million (Q4 2025), -$31.5 million (Q3 2025), and -$15.9 million (Q2 2025) per Business Quant data.